Does Affinity Health Plan Cover Eliquis?

What Is Eliquis and Why Do Doctors Prescribe It?

Eliquis (apixaban) is an oral, direct-acting factor Xa inhibitor approved by the FDA in December 2012 to reduce the risk of stroke and systemic embolism in adults with nonvalvular atrial fibrillation (NVAF). It is also approved for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for VTE prophylaxis following elective hip or knee replacement surgery. The FDA product label is publicly available through FDA AccessData.

Mechanism of Action

Apixaban selectively inhibits free and clot-bound factor Xa, interrupting the coagulation cascade at a point upstream of thrombin generation. Because it does not require routine INR monitoring, it offers a practical advantage over warfarin for many patients. The full pharmacology is described in the NIH drug monograph.

FDA-Approved Indications at a Glance

• Stroke and systemic embolism prevention in nonvalvular AF
• Treatment of DVT and PE
• Reduction in risk of recurrent DVT and PE
• Prophylaxis of DVT following hip or knee replacement surgery

Each indication carries its own dosing schedule. The AF dose is 5 mg twice daily (reduced to 2.5 mg twice daily if two of three criteria are met: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher). This dosing nuance matters for prior-authorization documents because payers sometimes flag doses that deviate from the label without clinical justification.

The Clinical Evidence Supporting Eliquis Coverage Decisions

Payers, including Medicaid managed-care organizations like Affinity Health Plan, base formulary decisions partly on clinical-evidence reviews. Understanding the trial data helps members and prescribers write stronger prior-authorization letters.

ARISTOTLE Trial (Atrial Fibrillation)

The ARISTOTLE trial enrolled 18,201 patients with NVAF and randomized them to apixaban 5 mg twice daily or dose-adjusted warfarin. Published in the New England Journal of Medicine, the trial showed apixaban reduced the primary endpoint of stroke or systemic embolism by 21% relative to warfarin (1.27% vs. 1.60% per year; hazard ratio 0.79; 95% CI 0.66-0.95; P<0.001 for noninferiority, P=0.01 for superiority). Major bleeding occurred in 2.13% of apixaban patients per year versus 3.09% with warfarin, a 31% relative risk reduction (P<0.001). These numbers are cited directly in prescriber letters to justify coverage.

AMPLIFY Trial (DVT and PE Treatment)

AMPLIFY enrolled 5,395 patients with acute DVT or PE. Published in the New England Journal of Medicine, the study demonstrated apixaban was noninferior to enoxaparin plus warfarin for recurrent VTE or VTE-related death (2.3% vs. 2.7%; relative risk 0.84; 95% CI 0.60-1.18; P<0.001 for noninferiority) while cutting major bleeding by 69% (0.6% vs. 1.8%; P<0.001). Payers reviewing DVT/PE prior-authorization requests will encounter these figures repeatedly.

ADVANCE-3 Trial (Post-Surgical Prophylaxis)

ADVANCE-3 assessed apixaban 2.5 mg twice daily versus enoxaparin 40 mg once daily in 5,407 patients undergoing total hip replacement. The apixaban arm achieved a 64% relative risk reduction in the composite of asymptomatic or symptomatic DVT, nonfatal PE, and all-cause death compared to enoxaparin, as published in the New England Journal of Medicine. This trial is frequently cited in orthopedic surgery prior-authorization submissions.

ACC/AHA Guideline Position

The 2023 ACC/AHA Atrial Fibrillation Guideline, published in the Journal of the American College of Cardiology and accessible via PubMed, gives a Class I recommendation (Level of Evidence: A) for NOACs over warfarin in patients with NVAF who are eligible for anticoagulation. Apixaban is one of four NOACs named in that Class I statement.

How Affinity Health Plan Formularies Work

Affinity Health Plan is a New York-based managed-care organization offering Medicaid, Child Health Plus, Essential Plan, and in some years commercial products. Each product line maintains a separate formulary that is updated at least annually per CMS and New York State Department of Health requirements.

Formulary Tiers and Cost Sharing

Most Affinity formularies use a four- or five-tier structure:

| Tier | Drug Category | Typical Member Copay | |------|--------------|----------------------| | 1 | Generic preferred | $0-$5 | | 2 | Generic non-preferred | $10-$20 | | 3 | Brand preferred | $35-$60 | | 4 | Brand non-preferred | $75-$120 | | 5 | Specialty | 20%-33% coinsurance |

Eliquis typically lands at Tier 3 or Tier 4 on commercial-style plans. On Medicaid plans, cost sharing is often minimal or zero after state-mandated limits, but prior authorization requirements still apply.

Step Therapy and Prior Authorization

Step therapy is a cost-control tool that requires patients to try a lower-cost drug (often warfarin or generic rivaroxaban where available) before the plan approves the requested drug. New York State enacted Insurance Law Section 3216-a to regulate step-therapy protocols, giving physicians a formal process to request a step-therapy exemption when clinical circumstances warrant. Affinity must comply with those state rules.

Common clinical reasons that support a step-therapy exemption or direct prior authorization approval for apixaban include:

• Documented labile INR on warfarin (two or more out-of-range values in the past 12 months)
• History of warfarin-related major bleeding
• Inability to obtain regular INR monitoring
• Drug interactions that make stable warfarin management difficult
• Physician attestation that a NOAC is clinically superior for this specific patient

The American Heart Association's anticoagulation guidance notes that patient-specific factors, including adherence patterns and comorbidities, should drive NOAC selection rather than cost alone.

How to Check Whether Your Affinity Plan Covers Eliquis Right Now

Formularies change every January 1 and sometimes mid-year with 60-day notice. A coverage determination from 2023 may not apply to your 2025 plan.

Step 1: Use the Online Drug Lookup

Go to affinityplan.org and manage to the formulary or drug search section. Enter "apixaban" or "Eliquis," select your plan name and plan year, and note the tier and any PA flag.

Step 2: Call Member Services

The member services number is printed on the back of your insurance card. Ask specifically: "Is apixaban (Eliquis) covered on my formulary, what tier is it, and is prior authorization required?" Request a case reference number for your records.

Step 3: Ask Your Pharmacy

A retail pharmacist can run a test claim against your Affinity benefit in real time. The claim response will show whether the drug is covered, the copay amount, and whether a PA is needed before dispensing.

Step 4: Request a Coverage Determination in Writing

If you need a formal written answer, submit a coverage determination request through Affinity's member appeals and grievances process. Under New York State rules and federal Medicaid rules, Affinity must respond to standard requests within 72 hours and urgent requests within 24 hours.

The four-step verification process above is the HealthRX Formulary Confirmation Framework, designed to produce a documented paper trail before a prescription is denied at the pharmacy counter. Each step generates a record: a screenshot, a case reference number, a pharmacy rejection code, or a written determination. That documentation is essential if an appeal becomes necessary.

What to Do If Affinity Denies Eliquis Coverage

A denial is not the end of the road. Systematic appeals succeed at meaningful rates, particularly when the prescriber submits clinical documentation promptly.

Internal Appeal

File an internal appeal with Affinity within 60 days of the denial notice. Include:

1. The prescriber's letter of medical necessity citing ARISTOTLE, AMPLIFY, or ADVANCE-3 data as applicable.
2. The relevant ACC/AHA guideline Class I recommendation for NOACs.
3. Clinical documentation supporting any step-therapy exemption (INR logs, prior bleeding events, drug-interaction records).

External Appeal

New York State law allows members to request an independent external appeal through the New York State Department of Financial Services (DFS) if the internal appeal is denied. The DFS external appeal process is described at dfs.ny.gov. An independent organization reviews the clinical evidence without Affinity's input.

Expedited Review for Urgent Situations

If a patient is currently hospitalized or at immediate risk of stroke or thromboembolism, an expedited review shortens the timeline to 24-72 hours. The prescriber must attest to the urgency in writing.

Cost Reduction Options If Coverage Is Limited or Denied

Even when coverage is delayed or cost sharing is high, several programs can reduce out-of-pocket expense substantially.

Bristol Myers Squibb Eliquis 360 Support

The Eliquis 360 Support program, administered through Bristol Myers Squibb and Pfizer, offers a $10-per-month copay card for eligible commercially insured patients. The program is not available to patients covered exclusively by federal or state government programs (Medicare, Medicaid, TRICARE). Full eligibility terms are at bms.com. The FDA guidance on patient assistance programs provides context on the regulatory framework around such programs.

NeedyMeds and RxAssist

The databases at NeedyMeds and RxAssist compile free and reduced-cost drug programs. Neither site is on the HealthRX citation allow-list, but prescribers routinely direct uninsured or underinsured patients to these resources.

Generic Alternatives and Therapeutic Substitution

No FDA-approved generic apixaban exists as of early 2025. Generic rivaroxaban (Xarelto) also lacks FDA approval. However, the anticoagulation literature recognizes several scenarios where dabigatran or rivaroxaban might be therapeutically substituted. The 2023 ACC/AHA AF guidelines on PubMed state that all four approved NOACs (apixaban, rivaroxaban, dabigatran, edoxaban) carry Class I, Level A recommendations for NVAF, meaning a substitution to a covered NOAC may be clinically acceptable if the prescriber agrees.

A head-to-head comparison published in the Journal of the American Medical Association found that in Medicare patients with AF, apixaban was associated with lower rates of major bleeding compared to rivaroxaban (hazard ratio 0.68, 95% CI 0.56-0.82), which is relevant when discussing therapeutic substitution with patients who have bleeding risk factors. This 2019 observational study (N=581,451 patients) represents one of the largest real-world comparisons of these agents.

Clinical Considerations for Prescribers Writing the PA Letter

A strong prior-authorization letter addresses the payer's specific criteria directly. Generic letters fail more often.

Key Elements of an Effective PA Letter

• Patient's CHA2DS2-VASc score for AF patients (score of 2 or higher in men, 3 or higher in women meets guideline threshold for anticoagulation per the AHA/ACC guidelines on PubMed)
• Specific contraindication or failure of the step-therapy drug, documented with dates
• Relevant comorbidities: CKD stage, liver function, fall risk, medication list with drug interactions
• Citation of ARISTOTLE or AMPLIFY with the specific outcome data relevant to this patient's indication
• The ACC/AHA Class I recommendation language verbatim: "For patients with AF who have at least one risk factor for stroke, antithrombotic therapy with an oral anticoagulant is recommended."

Renal Dosing Documentation

Apixaban requires dose reduction to 2.5 mg twice daily when two of three criteria are present: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher. If the prescriber is ordering 2.5 mg, the PA letter should state those criteria explicitly. Failure to document this is a common reason payers request additional information. The renal-dosing pharmacokinetics are described in this NIH pharmacology review.

Duration of Therapy Statements

Payers sometimes approve apixaban for 30 or 90 days at a time for DVT/PE treatment. For AF, indefinite anticoagulation is guideline-supported. The PA letter should specify "indefinite duration" for AF patients and cite the guideline language. For post-surgical prophylaxis after hip replacement, the FDA label supports 35 days; for knee replacement, 12 days. Specifying the duration in the PA request reduces back-and-forth with the plan.

Special Populations and Coverage Nuances

Patients on Medicaid Through Affinity

Medicaid patients enrolled in Affinity's managed-care plan face state-set copay limits (currently $3 per brand drug per month in New York for most Medicaid enrollees). Prior authorization rules still apply, but cost is rarely the primary barrier. Continuity of care rules under 42 CFR 438.62 require Medicaid managed-care plans to cover ongoing treatments for newly enrolled members for up to 90 days, which may provide temporary coverage while a PA is processed. The CMS Medicaid managed-care final rule context is available at CMS.gov / Medicaid.

Essential Plan Members

New York's Essential Plan is a low-premium product for individuals who do not qualify for Medicaid but have income between 138% and 200% of the federal poverty level. Affinity participates as an Essential Plan carrier. The Essential Plan formulary follows New York State's Preferred Drug List, where anticoagulants including apixaban appear with prior authorization requirements. The New York State DOH Medicaid Preferred Drug Program publishes the current PDL.

Pregnant Patients

The FDA label for apixaban includes a warning that limited data exist on use during pregnancy. The ACOG Practice Bulletin on Thromboembolism in Pregnancy recommends low-molecular-weight heparin as the preferred anticoagulant during pregnancy; NOACs are generally not recommended. Coverage requests for Eliquis in pregnant patients are unlikely to be approved based on current guidelines, and prescribers should document the clinical rationale explicitly if they believe apixaban is the only appropriate option.

Understanding the Bigger Picture: Atrial Fibrillation Burden and the Cost of Under-Treatment

Atrial fibrillation affects approximately 6 million Americans, a figure the CDC projects could reach 12 million by 2030. Stroke complicating AF is associated with higher mortality and greater disability than non-AF stroke. The American Heart Association's 2024 Heart Disease and Stroke Statistics report that AF-related strokes account for roughly 15% to 20% of all ischemic strokes.

From a payer perspective, the cost of an AF-related stroke (acute hospitalization, rehabilitation, long-term disability) substantially exceeds the annual cost of anticoagulation. A pharmacoeconomic analysis published in the American Journal of Managed Care estimated that apixaban was cost-effective versus warfarin in the U.S. Context at a willingness-to-pay threshold of $50,000 per quality-adjusted life year. That cost-effectiveness data can be included in PA letters when arguing against step therapy through warfarin.

Warfarin remains effective when INR is well-controlled, with a time-in-therapeutic range (TTR) target of 65% or higher. Below that threshold, the stroke-prevention benefit erodes substantially, as the Connolly et al. Analysis in Circulation demonstrated. Documenting a patient's historical TTR is one of the most powerful pieces of evidence in a PA letter for apixaban when warfarin has already been tried.

Monitoring and Follow-Up After Starting Eliquis

Apixaban requires no routine coagulation monitoring, which contrasts sharply with warfarin. However, periodic clinical assessment is still important.

Renal Function Monitoring

The FDA prescribing information recommends periodic assessment of renal function, particularly in patients 75 years or older or those with baseline renal impairment, since declining renal function may trigger the dose-reduction criteria. Clinicians should check serum creatinine at least annually, or more often if the patient has CKD stage 3 or higher.

Drug Interaction Screening

Apixaban is a CYP3A4 and P-glycoprotein substrate. Strong dual inhibitors of both pathways (such as ketoconazole, itraconazole, ritonavir) increase apixaban exposure by approximately 2-fold, warranting dose reduction to 2.5 mg twice daily if the patient is not already on the reduced dose. Strong dual inducers (such as rifampin, carbamazepine, phenytoin) reduce apixaban exposure by about 54% and should prompt a consideration of alternative anticoagulation. These interactions are detailed in the NIH drug interaction database.

Bleeding Risk Assessment

The HAS-BLED score estimates bleeding risk in anticoagulated AF patients. A score of 3 or higher signals elevated bleeding risk but does not contraindicate anticoagulation. The AHA/ACC AF guideline commentary on PubMed notes that modifiable HAS-BLED risk factors (hypertension, concurrent antiplatelet or NSAID use, labile INR on prior warfarin, alcohol use) should be addressed before anticoagulation is stopped.